lumacaftor has been researched along with Polycystic-Kidney--Autosomal-Dominant* in 2 studies
2 other study(ies) available for lumacaftor and Polycystic-Kidney--Autosomal-Dominant
Article | Year |
---|---|
VX-809 mitigates disease in a mouse model of autosomal dominant polycystic kidney disease bearing the R3277C human mutation.
Topics: Aminopyridines; Animals; Benzodioxoles; Cystic Fibrosis Transmembrane Conductance Regulator; Cysts; Female; Kidney; Male; Mice; Mice, Inbred C57BL; Polycystic Kidney, Autosomal Dominant | 2021 |
A potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector.
Autosomal dominant polycystic kidney disease (ADPKD) is associated with progressive enlargement of cysts, leading to a decline in function and renal failure that cannot be prevented by current treatments. Mutations in Topics: Aminopyridines; Animals; Benzodioxoles; Calcium; Cell Line; Cell Proliferation; Cyclic AMP; Cystic Fibrosis Transmembrane Conductance Regulator; Cysts; Heat-Shock Proteins; Kidney; Mice; Mice, Inbred C57BL; Polycystic Kidney, Autosomal Dominant; Transcription Factor CHOP | 2018 |